CLINICAL_TRIALS trial_result · 2011-03-07

Clinical Trial Update: MK0249 for the Treatment of Cognitive Impairment in Patients With Schizophrenia (0249-016) [Phase 2]

Phase 2 trial of MK0249 for cognitive impairment in patients with paranoid schizophrenia has completed, with results posted in 2011.

Upgrade for the full analysis, importance score, and drug timeline.

Sponsor: Merck Sharp & Dohme LLC | Conditions: Paranoid Schizophrenia | Phase 2 | Status: COMPLETED | Results posted: 2011-03-07